Photo Credit: Getty Images
Novo Nordisk, the maker of the diabetes and weight-loss drug Ozempic, is facing mounting legal pressure as more than 2,000 people have filed lawsuits alleging the drug caused serious, life-altering health complications. The combined damages being sought are estimated to exceed $2 billion, making the case one of the largest pharmaceutical lawsuits in recent years.
The plaintiffs claim that the company failed to properly warn users and doctors about the potential dangers associated with Ozempic, particularly as the drug’s popularity soared among people seeking rapid weight loss. Originally approved to treat type-2 diabetes, Ozempic has been widely used off-label for slimming purposes, a trend that fueled its rise to mainstream recognition.
According to the lawsuits, patients have experienced devastating health problems after taking the medication. Among the most severe are gastroparesis, or stomach paralysis, which leaves patients unable to properly digest food, often resulting in persistent nausea and vomiting. Others have reported intestinal blockages that required emergency medical treatment, gallbladder disease that in some cases led to surgery, and painful pancreatitis. Kidney damage has also been alleged, with some patients claiming long-term impairment after using the drug. Perhaps most alarming are reports of sudden vision loss, with users developing a condition that can cause permanent blindness in one or both eyes.
The growing number of complaints has been consolidated into a large federal case under multidistrict litigation, allowing judges to coordinate pretrial motions and evidence more efficiently. Bellwether trials, which will test how juries respond to representative claims, are expected to begin in 2026.
Novo Nordisk has denied any wrongdoing, stating that Ozempic is safe when used as directed and that all known risks are disclosed in product labeling. Attorneys for the plaintiffs argue, however, that the company downplayed the dangers while aggressively promoting the drug’s weight-loss benefits, encouraging off-label use without sufficient safeguards.
The stakes are high not only for the manufacturer but for the future of other GLP-1 drugs in the same class. A major settlement or verdict against Novo Nordisk could force significant changes in how these medications are marketed and prescribed. For thousands of patients who say their lives have been permanently changed, the lawsuit represents both a chance at compensation and a push for greater accountability in the pharmaceutical industry.
